A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2019
Price : $35 *
At a glance
- Drugs INCB-81776 (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 05 Mar 2019 Planned End Date changed from 1 Nov 2019 to 1 Oct 2020.
- 05 Mar 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Apr 2020.
- 10 Jul 2018 Status changed from not yet recruiting to recruiting.